A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

Summary

This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Irritable Bowel Syndrome

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

September 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites